Notes
OCULAR (priority, the reason this ADC qualifies): from SGO 2022 conference abstract (Gynecol Oncol 2022;166 Suppl 1, abstr 076), pooled Phase 1b expansion n=97 across 36-43 mg/m2 + 80 mg flat cap, Q4W IV. Blurred vision 41% any / 6% G3+; keratopathy 9% G3+ (any-grade keratopathy NOT reported -> ae_corneal_pct left blank). oae_any_pct=41 (max any-grade PT = blurred vision); oae_g3plus_pct=9 (max G3+ PT = keratopathy). Dominant tissue corneal/visual; auristatin-F (MMAF-like, but AF-HPA) off-target ocular-surface toxicity, NOT on-target (NaPi2b not corneal-expressed). Reversibility not explicitly stated for UpRi (class effect typically reversible) -> Unknown. Grading scale not stated in abstract (likely CTCAE v5.0) -> left blank.
NON-OCULAR: most common TRAEs were fatigue, nausea, transient AST increase, thrombocytopenia, decreased appetite; most common G3+ were transient AST increase, fatigue, anemia, thrombocytopenia. EXACT percentages for hepatic (AST), hematologic (thrombocytopenia/anemia/neutropenia), and GI (nausea) are behind paywalled abstract/journal sources (ScienceDirect/Elsevier, ResearchGate, OncLive/TargetedOnc all returned 403) and are therefore left BLANK per the convention (blank != 0). Dose reductions 28% and discontinuations 10% due to TRAEs (n=97). Peripheral neuropathy not prominent (AF-HPA designed for low PN); no PN rate retrieved -> blank. Pneumonitis ~9.6% included as a D-tier Pulmonary row (denominator uncertain).
COMPOSITION/CHEMISTRY: anti-NaPi2b (SLC34A2) humanized IgG1-kappa antibody XMT-1535; Dolaflexin platform = hydrophilic Fleximer/PHF polyacetal polymer (3-5 polymers per mAb) carrying ~10-15 AF-HPA, attached by random-cysteine maleimide thioether (cleavable). DAR: ADCdb 10-12, ADC Review 12-15, preclinical 10-15 -> reported ~12 (10-15). Payload AF-HPA = auristatin F hydroxypropylamide (PubChem CID 71135741; C43H74N6O8, MW 803.1, XLogP 4.3, TPSA 170); controlled bystander, metabolized intratumorally to auristatin F (AF). Charge +1 = physiological protonation of the basic amine (C-terminus masked as hydroxypropylamide -> neutral, membrane-permeable, unlike charged MMAF; PubChem formal charge 0).
LINKER PHYSCHEM: ADCdb linker LIN0SWMHT is a POLYMER linker (Dolaflexin/Fleximer) with no discrete SMILES/formula/MW/TPSA/xLogP (not chemically defined for a single small molecule) -> linker_smiles/formula/mw/tpsa/xlogp left blank.
PROGRAM STATUS: discontinued 2023. UPLIFT (NCT03319628 registrational cohort) missed primary endpoint (investigator ORR 15.6%, 22/141 NaPi2b+); UP-NEXT Phase 3 maintenance (NCT05329545) terminated Sep 2023.
DERIVED columns intentionally NOT filled (computed downstream): severity, FcgammaR/C1q status, dna_damage subtype, stability conditional/unconditional, HCA/HPA expression.